PI3K Inhibitor Treatment Ameliorates the Glucocorticoid Insensitivity of PBMCs in Severe Asthma

Clinical and Translational Medicine - United Kingdom
doi 10.1186/s40169-020-0262-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Benralizumab for the Treatment of Severe Eosinophilic Asthma

Prescriber
Pharmacology
2018English

Dupilumab Efficacy and Safety in Moderate-To-Severe Uncontrolled AsthmaEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

Pediatrics
Child HealthPediatricsPerinatology
2018English

Benralizumab: A Unique IL-5 Inhibitor for Severe Asthma

Journal of Asthma and Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2016English

Oxygen Treatment for Acute Severe Asthma

BMJ
2001English

Prm50 - Improvement of Efficiency of Severe Atopic Asthma Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Biological Treatment of Severe Asthma: New Objectives and New Treatment Options

Medical Council
2019English

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

PI3K Inhibitor–Induced Insulin Feedback Activates PI3K Signaling

Cancer Discovery
Oncology
2018English

Benralizumab in the Treatment of Severe Asthma: Design, Development and Potential Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy